Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.

ABSTRACT:

Background

Preexposure prophylaxis using antiretroviral agents has been shown to effectively prevent human immunodeficiency virus type 1 (HIV-1) acquisition in high-risk populations. However, the efficacy of these regimens is highly variable, which is thought to be largely due to the varying degrees of adherence to a daily intervention in the populations. Passive immunization using broadly neutralizing antibodies (bNAbs) against HIV-1, with their relatively long half-life and favorable safety profile, could provide an alternative to daily preexposure prophylaxis. However, most bNAbs have a limited breadth, only neutralizing 70%-90% of all HIV-1 strains.

Methods

To overcome the problem of limited antiviral breadth, we proposed that targeting human CD4 and HIV-1 envelope prote

SUBMITTER: Song R 

PROVIDER: S-EPMC5123706 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature